Get the Right Drug, At the Right Dose, the First Time.

Personalized Medication. Guided by Your DNA

Discover how your genes influence your response to medications.

What is Pharmacogenetics (PGx) Testing?

Pharmacogenetics testing investigates how a person’s genetic makeup may affect how their body processes certain medications.

Genes affect how the body breaks down, activates, and responds to a medication. If a drug is metabolized too quickly, too slowly, or not at all, the prescribed dose may be ineffective or cause harm. In some cases, this can lead to serious side effects, including toxicity, while in others, the medication may have little or no therapeutic benefit for the condition being treated.

A pharmacogenetic test (PGx) looks at an individual’s genes and how they respond to different types of medications. Results from a pharmacogenetic test do not change over time, so they can be stored and referred to throughout a person’s life.

Precision Prescribing Powered by Your Genetics

Our Pharmacogenetics Panel

Guides in Optimal Medication Selection

Identifies risk of Adverse Drug Reaction

Supports Informed Decision-Making

Why Pharmacogenetics (PGx) Testing?

Our Pharmacogenetics (PGx) test covers drugs across a broad range of therapeutic areas, so you can be as confident as possible that your medications are safe and effective for you.

  • Psychiatry

    38 Drugs

  • Anesthesiology

    5 Drugs

  • Cardiology

    22 Drugs

  • Dermatology

    10 Drugs

  • Gastroenterology

    10 Drugs

  • Immunology

    4 Drugs

  • Infectious Disease

    10 Drugs

  • Neurology

    6 Drugs

  • Oncology

    9 Drugs

  • Pain

    15 Drugs

  • Urology

    4 Drugs

OncoHelix Pharmacogenetics (PGx)

  • PGx testing reports on 14 genes and 59 variants (SNPs and CNVs) encoding drug metabolism enzymes (DMEs) and transport proteins, delivering high analytical sensitivity and specificity.

    • 2C Cluster (g.94645745G>A)

    • CYP2B6 (*4, 6, 18, 36)

    • CYP2C19 (6, 7, 10, 17),

    • CYP2C8 (1C g.4726T>G, 2 g.16149A>T, 3 g.7225G>A, c.416G>A),

    • CYP2C9 (*2, 5, 6, 12, 71, 15, 16, 8, 29 g.38962C>A, c.835C>A),

    • CYP2D6 (*2 g.7870C>T, 2, 3, 4, 6, 7, 9, 10, 12, 17, 21, 29, 41, 49),

    • CYP3A4 (22),

    • CYP3A5 (*3, 6, 7),

    • CYP4F2 (c.1297G>A [*3 or 4]),

    • DPYD (c.557A>G, c.868A>G, c.1129-5923C>G HapB3, c.1236G>A HapB3, c.1679T>G 13, c.1905+1G>A 2A, c.2279C>T, c.2846A>T),

    • NUDT15 (3, 4),

    • SLCO1B1 (5, 14, 15, 9),

    • TPMT (2, 3A, 3B, *3C),

    • VKORC1 (c.-1639G>A),

    • TERT

  • Abrocitinib, Acenocoumarol, Amiodarone, Amitriptyline, Amoxapine, Amphetamine, Aripiprazole, Aspirin, Atenolol, Atorvastatin, Atomoxetine, Azathioprine, Bisoprolol, Brivaracetam, Brexpiprazole, Capecitabine, Carisoprodol, Carvedilol, Celecoxib, Cevimeline, Citalopram, Clobazam, Clomipramine, Clonidine, Clopidogrel, Clozapine, Codeine, Darifenacin, Desipramine, Dexlansoprazole, Dextromethorphan/Bupropion, Diazepam, Donepezil, Doxepin, Dronabinol, Duloxetine, Eliglustat, Elagolix, Erdafitinib, Escitalopram, Esomeprazole, Efavirenz, Fesoterodine, Flecainide, Flurbiprofen, Fluvastatin, Fluoxetine, Fluvoxamine, Fosphenytoin, Fucytosine, Galantamine, Gefitinib, Haloperidol, Hydrocodone, Ibuprofen, Iloperidone, Imipramine, Lansoprazole, Lofexidine, Lornoxicam, Lovastatin, Mavacamten, Meclizine, Meloxicam, Mercaptopurine, Metoclopramide, Methylphenidate, Metoprolol, Mirabegron, Mirtazapine, Moclobemide, Nateglinide, Nebivolol, Nortriptyline, Olanzapine, Oliceridine, Omeprazole, Ondansetron, Oxycodone, Pantoprazole, Paroxetine, Perphenazine, Phenytoin, Pimozide, Pitavastatin, Pitolisant, Piroxicam, Pravastatin, Prasugrel, Propafenone, Propranolol, Quetiapine, Rabeprazole, Risperidone, Rosuvastatin, Sertraline, Simvastatin, Siponimod, Tacrolimus, Tamoxifen, Tamsulosin, Tegafur, Tenoxicam, Thioridazine, Thioguanine, Ticagrelor, Tolterodine, Tramadol, Trimipramine, Tropisetron, Valbenazine, Venlafaxine, Viloxazine, Voriconazole, Vortioxetine, Warfarin, Zuclopenthixol

  • Our PGx reporting follows established genetics-based prescribing guidelines and drug labels from the following sources:

    1. Food and Drug Administration (FDA)

    2. Clinical Pharmacogenetics Implementation Consortium (CPIC)

    3. Dutch Pharmacogenetics Working Group (DPWG)

    A person’s genes do not change, but the recommendations may be updated as new guidelines emerge. An updated report can be generated at any time on the patient’s request.

Ordering a Test

Step 1 Complete the OncoHelix PGx Requisition.

  • Patient details are filled out at the top of the requisition under “Patient Information.”
  • Physician details are completed under “Order Information.”
  • Details about any diagnosis and/or medicine(s) being investigated are to be provided under "Diagnosis."

Step 2 Collect Sample using the Swab Kit and Ship 

Detailed instructions collecting sample using a buccal swab will be provided within the kit. The kit will also contain a prepaid shipping label which can be used once sample collection is complete.

Step 3 OncoHelix will contact you in 3 business days.

An OncoHelix customer navigator will contact you within 3 business days on receiving the kit with payment istructions. A secure link will be sent to your preferred email address and all major credit cards are accepted.

Step 4 A PGx Report will be sent to you in 10 days.

The PGx test requires 10 days to complete: starting from the arrival time of the kit to the OncoHelix Lab in Calgary, Alberta to the final result reviewed by our team of pathologists. When the test is completed, and your pharmacogenomic profile is analyzed,  you and your ordering physician will receive an electronic report.

Requisition Form